Informative Report On (COVID-19 Updates) Rest of the World Factor VIII Deficiency Treatment Market is Generating Revenue of US$ 3.06 Billion by 2027
The Rest of the World Factor VIII Deficiency Treatment Market analysis report speaks about the growth rate till 2027 manufacturing process, Growth, key factors driving this market with sales, revenue, and price analysis of lead manufacturers, distributors, traders and dealers of Rest of the World Factor VIII Deficiency Treatment.
Coherent Market Insights always aims at offering their clients an in-depth analysis and the best research material of the various market. The “Rest of the World Factor VIII Deficiency Treatment Market projected to develop with growing expansion prospects”. The Rest of the World Factor VIII Deficiency Treatment Market report presents a calculated opinion of the analyzed Rest of the World Factor VIII Deficiency Treatment Market data. It explains various opportunities dedicated to different industries, suppliers, organizations, and associations offering various products and services such as offering them precise guidance for their expansion in the competition for reliable services to consumers. The report provides detailed information on key competitors in the market and on emerging companies with significant market share based on demand, revenue, sales, high-quality product manufacturers, and service providers.
The prominent players in the Rest of the World Factor VIII Deficiency Treatment Market are VIII deficiency treatment market include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S.
Over the forecast period, the rest of the world factor VIII deficiency treatment market is expected to rise due to an increase in the incidence and prevalence of hemophilia. According to the World Federation of Hemophilia (WFH) figures from 2018, there were approximately 440,000 individuals worldwide and hemophilia, with approximately 173,000 people diagnosed with hemophilia A or B in 2017.
Due to the increasing need for factor VIII deficiency therapy, major players are concentrating on product or medication releases and approvals. The FDA approved Kedrion’s Koate Double Viral Inactivation (DVI) Anti-hemophilic Factor with Mix2Vial for the treatment of factor VIII deficiency in March 2016. Furthermore, in May 2018, Chugai Pharmaceutical Co., Ltd., a Roche Group subsidiary, released HEMLIBRA, an anticoagulation factor X humanized bio-specific monoclonal antibody factor VIII replacement for routine prophylaxis to prevent or mitigate bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) who are taking factor VIII inhibitors.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/3257
Due to the favorable regulatory scenario and guidance by government authorities, Asia Pacific is expected to deliver attractive business opportunities in the rest of the world factor VIII deficiency treatment market over the forecast period, which is expected to accelerate market growth over the forecast period. As per the World Hemophilia Foundation’s 2015 study on National Tenders for the Purchasing of Clotting Factor Concentrates, the Brazilian Health Surveillance Agency (ANVISA), which is the national authority for product control and inspection, the purchase of clotting factor concentrates in Brazil must be authorized and licensed by the Brazilian Health Surveillance Agency (ANVISA).
Furthermore, several key market players are focused on partnerships with the aim of developing new therapies for the treatment of deficiency, which is expected to aid market growth over the forecast period. RCSI, a Dublin-based international health sciences agency, and Bayer AG announced a scientific partnership in August 2018 to explore alternative therapeutic strategies for people with extreme hemophilia. Sangamo Therapeutics, Inc., a genomic medicine firm, and Pfizer Inc. have announced a global partnership and licensing agreement in May 2017 for the production and commercialization of a gene therapy-based medication for the treatment of hemophilia A.
Key Takeaways
Due to increasing cases of hemophilia and approvals and releases of new products and medicines, the rest of the world factor VIII deficiency treatment market is expected to grow at a CAGR of 4.7 percent over the forecast period. As per the National Hemophilia Foundation’s 2018 survey, one out of every 10,000 people is born with hemophilia A due to clotting factor VIII deficiency, and one out of every 50,000 people is born with hemophilia B due to clotting factor IX deficiency.
Due to its cost effectiveness, the plasma related coagulation factor concentrates segment dominated the factor VIII deficiency drug market in 2018. According to studies released by the World Federation of Hemophilia in 2016, demand for plasma-derived coagulation factors is higher than for recombinant coagulation concentrate, owing to its ease of distribution in developing economies and low costs.
Key companies contributing in the rest of the world factor VIII deficiency treatment market are CSL Behring, Bayer AG, Biogen, Inc., Kedrion, Baxter International, Inc., Novo Nordisk A/S, Pfizer, Inc., F. Hoffmann-La Roche AG, and Ferring B.V.
Main points in Rest of the World Factor VIII Deficiency Treatment Market Report Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Rest of the World Factor VIII Deficiency Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Rest of the World Factor VIII Deficiency Treatment Industry Impact
Chapter 2 Global Rest of the World Factor VIII Deficiency Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Rest of the World Factor VIII Deficiency Treatment (Volume and Value) by Type
2.3 Global Rest of the World Factor VIII Deficiency Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Rest of the World Factor VIII Deficiency Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 6 East Asia Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 7 Europe Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 8 South Asia Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 9 Southeast Asia Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 10 Middle East Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 11 Africa Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 12 Oceania Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 13 South America Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Rest of the World Factor VIII Deficiency Treatment Business
Chapter 15 Global Rest of the World Factor VIII Deficiency Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
